Podcast: “Powerful Yet Unexplored”: Commit Biologics Tackles The Complement System

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.

In Vivo Podcast

Commit Biologics is a preclinical company developing a new class of therapeutics based on its Bispecific Complement Engager (BiCE) platform to treat autoimmune diseases and cancer.

Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics. (Fotograf Esben Zøllner Olesen)

The company is focused on advancing BiCE, designed to activate the complement system and induce the highly selective killing of cells of interest.

Speaking to the In Vivo podcast, Wandahl Pederson explained that “the unique thing about Commit’s technology is of course the BiCE technology. The B molecules have a unique ability to engage the C1Q, which is the first protein in the [classical] complement cascade.”

Although the company is yet to have any candidates in the clinic, its next steps will involve generating proof-of-concept data over the next year and selecting a candidate with the greatest potential for pipeline development.

“It’s critical for us that we identify the right asset, the most promising one, the one that differentiates the most. So, we allow ourselves some time to think about that before actually selecting the final candidates that we want to push forward,” said Pederson. 

The biotech has secured a cash runway leading to an estimated mid-2027. After launching in May 2024 with €16m in seed funding from Bioqube Ventures and Novo Holdings, Commit secured a €5.5m seed financing extension in January 2025 from Belgian investment company Korys, bringing its total funding to €21.5m.

In Vivo spoke to Wandahl Pederson about Commit Biologics’ ambitious attitude as it continues to develop its BiCE technology and search for collaborations both academically and professionally.

Timestamps:

Overview of the complement system and its role in the immune system – 02:50

BiCE technology - 05:22

New antibody development strategies – 07:50

Regulatory and pipeline strategies – 10:01

Seed funding and future opportunities - 14:32

Career history -17:15

Challenges facing the company and the industry - 19:00

More from Podcasts

Podcast: Inside MoonLake’s Fast-Track Vision And $500m Deal

 
• By 

MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

More from Leadership

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

 
• By 

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.